Weekly Analysts’ Ratings Changes for Erasca (ERAS)

A number of firms have modified their ratings and price targets on shares of Erasca (NASDAQ: ERAS) recently:

• 3/18/2026 – Erasca had its price target raised by JPMorgan Chase & Co. from $24.00 to $25.00. They now have an “overweight” rating on the stock.
• 3/16/2026 – Erasca had its price target raised by Guggenheim from $12.00 to $20.00. They now have a “buy” rating on the stock.
• 3/13/2026 – Erasca had its “buy” rating reaffirmed by Citigroup Inc..
• 3/13/2026 – Erasca had its price target raised by Piper Sandler from $11.00 to $18.00. They now have an “overweight” rating on the stock.
• 3/13/2026 – Erasca had its price target raised by Mizuho from $16.00 to $19.00. They now have an “outperform” rating on the stock.
• 3/13/2026 – Erasca had its price target raised by HC Wainwright from $15.00 to $20.00. They now have a “buy” rating on the stock.
• 3/10/2026 – Erasca was given a new $20.00 price target by Stifel Nicolaus.
• 1/27/2026 – Erasca had its “buy” rating reaffirmed by Guggenheim. They now have a $12.00 price target on the stock.
• 1/27/2026 – Erasca is now covered by Mizuho. They set an “outperform” rating and a $16.00 price target on the stock.
• 1/26/2026 – Erasca was given a new $10.00 price target by Morgan Stanley.
• 1/26/2026 – Erasca had its price target raised by HC Wainwright from $11.00 to $15.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In other Erasca news, insider Shannon Morris sold 20,000 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $15.04, for a total value of $300,800.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Ebun Garner sold 120,000 shares of the stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $5.59, for a total value of $670,800.00. Following the transaction, the general counsel directly owned 25,076 shares in the company, valued at $140,174.84. The trade was a 82.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 14.40% of the company’s stock.

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.